A Phase IV Study to Assess the Safety of Menveo Vaccine Being Used by HMO Subjects Aged 11-21 Years of Age
Phase of Trial: Phase IV
Latest Information Update: 26 Dec 2016
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions
- Sponsors Novartis Vaccines
- 26 Dec 2016 Results published in the Pediatrics
- 25 Feb 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Feb 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.